Differences in health values among patients, family members, and providers for outcomes in schizophrenia

Medical Care

Volumn 38, Issue 10, 2000, Pages 1011-1021

  Lenert, Leslie A ^a,f   Ziegler, Jennifer ^b   Lee, Tina ^b,c   Sommi, Roger ^d   Mahmoud, Ramy ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^f Hlth Serv Research and Development   (United States)

Author keywords

Computers; Extrapyramidal symptoms; Health care providers; Multimedia; Patients; Schizophrenia; Utility

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; ATTITUDE TO HEALTH; CLINICAL TRIAL; COMPARATIVE STUDY; CONSUMER; CROSS-SECTIONAL STUDY; EMPIRICAL APPROACH; FAMILY; FEMALE; HEALTH PERSONNEL ATTITUDE; HUMAN; MALE; MENTAL HEALTH THERAPIES; MULTICENTER STUDY; PARKINSON DISEASE; PROFESSIONAL PATIENT RELATIONSHIP; PSYCHOLOGY; QUALITY OF LIFE; RISK; SCHIZOPHRENIA; TEACHING; TREATMENT OUTCOME; UNITED STATES;

EMPIRICAL APPROACH; MENTAL HEALTH THERAPIES; PROFESSIONAL PATIENT RELATIONSHIP;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; ATTITUDE TO HEALTH; CONSUMER SATISFACTION; CROSS-SECTIONAL STUDIES; FAMILY; FEMALE; HUMANS; MALE; ODDS RATIO; PARKINSON DISEASE, SECONDARY; PATIENT SIMULATION; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; UNITED STATES;

EID: 0034293059     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-200010000-00005     Document Type: Article

References (35)

1. Gold M, Patrick D, Torrance G, et al. Cost-effectiveness in health and medicine. In: Gold M, Siegel J, Russel L, Weinstein M, eds. New York, NY: Oxford Press; 1996:101-102.
2. Amador XF, Strauss DH, Yale SA, et al. Awareness of illness in schizophrenia. Schizophr Bull 1991;17:113-132.
3. Atkinson M, Zibin S, Chuang H. Characterizing quality of life among patients with chronic mental illness: A critical examination of the self-report methodology. Am J Psychiatry 1997;154:99-105.
4. Startup M. Awareness of own and others' schizophrenic illness. Schizophr Res 1997;26:203-211.
5. Revicki D, Shakespear A, Kind P. Preference for schizophrenia related health states: A comparison of patients, caregivers, and psychiatrists. Int J Psychopharmacol 1996;11:101-108.
6. Lenert LA, Morss S, Goldstein MK, et al. Measurement of the validity of utility elicitations performed by computerized interview. Med Care 1997;35:915-920.
7. Lee T, Ziegler J, Sommi R, et al. Comparison of preferences for health outcomes in schizophrenia among stakeholder groups. J Psychiatr Res 2000;34:201-210.
8. Chouinard GPA. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol 1997;17:298-307.
9. Muma RD, Ross MW, Parcel GS, et al. Zidovudine adherence among individuals with HIV infection. AIDS Care 1995;7:439-447.
10. Nageotte C, Sullivan G, Duan N, et al. Medication compliance among the seriously mentally ill in a public mental health system. Soc Psychiatry Psychiatr Epidemiol 1997;32:49-56.
11. Budd RJ, Hughes IC, Smith JA. Health beliefs and compliance with antipsychotic medication. Br J Clin Psychol 1996;35:393-397.
12. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-651.
13. Greenstein S, Siegal B. Compliance and non-compliance in patients with a functioning renal transplant: a multicenter study. Transplantation 1998;66:1718-1726.
14. Morris LS, Schulz RM. Medication compliance: The patient's perspective. Clin Ther 1993;15:593-606.
15. Saigal S, Stoskopf BL, Feeny D, et al. Differences in preferences for neonatal outcomes among health care professionals, parents, and adolescents. JAMA 1999;281:1991-1997.
16. Holmes MM, Rovner DR, Rothert ML, et al. Women's and physicians' utilities for health outcomes in estrogen replacement therapy. J Gen Intern Med 1987;2:178-182.
17. Bennett C, Chapman G, Elstein A, et al. A comparison of perspectives on prostate cancer: Analysis of utility assessments of patients and physicians. Eur Urol 1997;32:86-88.
18. Goldstein MK, Clarke AE, Michelson D, et al. Developing and testing a multimedia: Presentation of a Health-State Description. Med Decis Making 1994;14:336-344.
19. Hedlund JL, Vieweg BW. The Brief Psychiatric Rating Scale: A comprehensive review. J Operational Psychiatry 1980;11:49-65.
20. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835.
21. Clarke AE, Goldstein MK, Michelson D, et al. The effect of assessment method and respondent population on utilities elicited for Gaucher disease. Qual Life Res 1997;6:169-184.
22. Lenert LA, Cher DJ, Goldstein MK, et al. Effects of search procedures on utility elicitations. Med Decis Making 1998;18:76-83.
23. Lenert LA, Soetikno R. Automated computer interviews to elicit utilities: Potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc 1997;4:49-56.
24. Llewellyn-Thomas HA, Sutherland HJ, et al. The measurement of patients' values in medicine. Med Decis Making 1982;2:449-462.
25. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
26. Lehman AF, Steinwachs DM. Patterns of usual care for schizophrenia: Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull 1998;24:11-20.
27. Lenert LA, Treadwell JR. Effects on preferences of violations of procedural invariance. Med Decis Making 1999;19:473-481.
28. Froberg D, Kane R. Methodology for measuring health-state preferences, II: Scaling methods. J Clin Epidemiol 1989;42:459-471.
29. Lenert LA, Treadwell JR, Schwartz CE. Associations between health status and utilities implications for policy. Med Care 1999;37:479-489.
30. Finn S, Bailey M, Schultz R, et al. Subjective utility ratings of neuroleptics in treating schizophrenia. Psychol Med 1990;20:843-848.
31. Rutten-van Molken MP, Bakker CH, van Doorslaer EK, et al. Methodological issues of patient utility measurement: Experience from two clinical trials. Med Care 1995;33:922-937.
32. Brabbins C, Butler J, Bentall R. Consent to neuroleptic medication for schizophrenia: Clinical, ethical and legal issues. Br J Psychiatry 1996;168:540-544.
33. Grisso T, Appelbaum PS, Hill-Fotouhi C. The MacCAT-T: A clinical tool to assess patients' capacities to make treatment decisions. Psychiatr Serv 1997;48:1415-1419.
34. Seckler AB, Meier DE, Mulvihill M, et al. Substituted judgment: How accurate are proxy predictions? Ann Intern Med 1991;115:92-98.
35. Marbella AM, Desbiens NA, Mueller-Rizner N, et al. Surrogates' agreement with patients' resuscitation preferences: Effect of age, relationship, and SUPPORT intervention: Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. J Crit Care 1998;13:140-145.